Hoppa till innehållet

OMXSPI+0,50%

S&P 500+0,80%

FTSE 100+0,54%

DAX+0,01%

NIKKEI+1,14%
Redeye: Calliditas - A cautious guide ahead of visible support later in 2024

Apart from the new label, Tarpeyo is supported by a higher price and 50-51% growth in prescribers and patient enrollment. Calliditas is setting a cautious guide ahead of visible and improved private pay conversion in 2024. We expect Calliditas to take a more proactive approach to the 2024 guide as the launch progresses, with added support from both the OLE study and the KDIGO revision later in 2024. Our updated view is a base case valuation of SEK 270 (280) and a Bull Case of SEK 390 (415) and a Bear Case of SEK 70 (70).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Calliditas - A cautious guide ahead of visible support later in 2024

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera